Enhancing Brain Processing Via Neurofeedback in Addictive Disorders
|ClinicalTrials.gov Identifier: NCT04252755|
Recruitment Status : Withdrawn (Study stopped prior to initiation due to COVID-19 complications)
First Posted : February 5, 2020
Last Update Posted : March 20, 2020
|Condition or disease||Intervention/treatment||Phase|
|Alcohol Drinking||Behavioral: EEG Neurofeedback||Not Applicable|
The NFB studies conducted to date have utilized a wide range of methodologies and NFB training protocols. The outcome measures of NFB efficacy have also varied widely. As mentioned above, the studies also used expensive, non-portable equipment which may limit the application of NFB in treatment settings. This study seeks to address these limitations by using a commercially-available neurotechnology, the Muse™ headband by InteraXon (Toronto, ON, Canada) and using their standard NFB protocol built into the device application. This will maximize the standardization and portability of the NFB as essentially an "out of the box" intervention. The outcome measures will also capture multiple relevant domains, including clinical outcomes (e.g., drinking motivation) and neurocognitive performance (e.g., cognitive control / response inhibition).
The purpose of this study is to investigate the effects of NFB training on measures of cognitive control and alcohol motivation among young adults who engage in heavy episodic drinking (defined as exceeding 4+/5+ drinks per occasion for men/women).
The study will examine whether NFB reduces motivation/attention and craving for alcohol and attentional bias to alcohol-related cues. The primary outcome will be assessed by changes in the alcohol purchase task and approach/avoidance task, which participants will complete pre- and post-NFB training.
A secondary outcome is to determine whether NFB results in transfer of heightened fronto-cortical activity to improvements on general executive functioning following 8 sessions of NFB training. The secondary outcome will be assessed via changes in neurocognitive tasks assessing behavioural inhibition, risky decision making, and executive functioning, all of which will be administered pre- and post-NFB training.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||0 participants|
|Intervention Model:||Single Group Assignment|
|Intervention Model Description:||This study will utilize a pre-post within-subjects design. All participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of neurofeedback, and finish with another session (post) after completion of all neurofeedback sessions.|
|Masking:||None (Open Label)|
|Official Title:||Enhancing Brain Processing Via Neurofeedback in Addictive Disorders: A Pilot Study|
|Estimated Study Start Date :||June 1, 2020|
|Estimated Primary Completion Date :||June 1, 2021|
|Estimated Study Completion Date :||June 1, 2021|
Within-subjects sessions of EEG neurofeedback
Behavioral: EEG Neurofeedback
Participants will undergo a baseline (pre) session, then be scheduled for 8 sessions of NFB, and finish with another session (post) after completion of all NFB sessions.
- Alcohol motivation [ Time Frame: 14 days ]Alcohol demand will be assessed via a hypothetical purchase task measuring self-reported consumption of alcohol across a range of prices. Primary dependent measure of this task is the amount of alcohol purchased and money spent.
- Alcohol approach/avoidance bias [ Time Frame: 14 days ]Approach-avoidance bias will be assessed via an implicit approach/avoidance task involving pushing or pulling images closer/farther away using a joystick. Primary dependent measure from this task is latency of response to alcohol vs. neutral images for the approach and avoidance conditions.
- Alcohol craving [ Time Frame: 14 days ]Subjective alcohol craving will be assessed via a visual analog scale (0-100, with 100 equal to maximum craving)
- Behavioural inhibition [ Time Frame: 14 days ]Behavioural inhibition will be assessed via computerized task of inhibitory control (go/no-go task) requiring suppression of inappropriate behavioural responses to "no-go" cues. Primary dependent measure is the percentage of correct trials and percentage of inhibitory failures
- Risky decision-making [ Time Frame: 14 days ]Risky decision making will be assessed via a Balloon Analogue Risk Task involving pumping a hypothetical balloon with an unknown air capacity. Each pump results in greater points earned, but a popped balloon results in loss of all accumulated points. Primary dependent variable from this task is the total number of pumps and number of exploded balloons. Higher values for each variable reflect greater risk taking
- Interference control [ Time Frame: 14 days ]Interference control will be assessed via the Erikson Flanker Task involving making a behavioural response to a central stimulus (left/right arrow) that is flanked by arrows that either point in same direction (congruent) or opposite direction (incongruent). Primary dependent variable is the percentage of correct trials in congruent vs incongruent conditions.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04252755
|St. Joseph's Healthcare Hamilton|
|Hamilton, Ontario, Canada, L8N3K7|
|Principal Investigator:||Michael Amlung, PhD||McMaster University|